NUVB
Nuvation Bio
No price yet
Announcements
Nothing here yet
Daily updates
FDA designations
Nothing here yet
News
- Nuvation Bio announced FDA approval of a supplemental NDA for IBTROZI with updated duration-of-response data in TKI-naïve advanced ROS1-positive NSCLCSep 17, 2026
- Nuvation Bio presented new analyses reinforcing the durable and consistent efficacy of IBTROZI across key patient subgroups with advanced ROS1-positive NSCLCSep 15, 2026
- Nuvation Bio received FDA Fast Track designation for safusidenib to treat IDH1-mutant gliomaAug 20, 2026
- Nuvation Bio's marketing authorization application for taletrectinib was validated in the UKJun 29, 2026
- Nuvation Bio receives FDA acceptance for supplemental NDA of IBTROZI with updated response duration dataMay 7, 2026